Transfusion‐associated adverse events incidence and severity after the implementation of an active hemovigilance program with 24 h follow‐up. A prospective cohort study

Abstract

AbstractBackgroundHemovigilance (HV) is usually based on voluntary reports (passive HV). Our aim is to ascertain credible incidence, severity, and mortality of transfusion‐associated adverse events (TAAEs) using an active HV program.Study Design and MethodsProspective cohort study to estimate transfusion risk after 46,488 transfusions in 5830 patients, using an active HV program with follow‐up within the first 24 h after transfusion. We compared these results to those with the previously established passive HV program during the same 30 months of the study. We explored factors associated with the occurrence of TAAEs using generalized estimating equations models.ResultsWith the active HV program TAAEs incidence was 57.3 (95% CI, 50.5–64.2) and mortality 1.1 (95% CI, 0.13–2.01) per 10,000 transfusions. Incidence with the new surveillance model was 14.0 times higher than with the passive. Most events occurred when transfusions had already finished (60.2%); especially pulmonary events (80.4%). Three out of five deaths and 50.3% of severe TAAEs were pulmonary. In the multivariate analysis surgical patients had half TAAEs risk when compared to medical patients (OR, 0.53; 95% CI, 0.34–0.78) and women had nearly twice the risk of a pulmonary event compared to men (OR, 1.84; 95% CI, 1.03–3.32). Patient's age, blood component type, or blood component shelf‐life were unrelated to TAAEs risk.DiscussionActive hemovigilance programs provide additional data which may lead to better recognition and understanding of TAAEs and their frequency and severity.